Article Text

Download PDFPDF

Original article
An SNX10 mutation causes malignant osteopetrosis of infancy
  1. Memet Aker1,2,
  2. Alex Rouvinski3,
  3. Saar Hashavia4,
  4. Asaf Ta-Shma4,
  5. Avraham Shaag1,2,
  6. Shamir Zenvirt1,2,
  7. Shoshana Israel5,
  8. Michael Weintraub6,
  9. Albert Taraboulos3,
  10. Zvi Bar-Shavit7,
  11. Orly Elpeleg1,2
  1. 1Monique and Jacques Roboh Department of Genetic Research, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
  2. 2Department of Genetic and Metabolic Diseases, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
  3. 3Department of Microbiology and Molecular Genetics, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
  4. 4Pediatric Department, Hebrew University Medical Center, Jerusalem, Israel
  5. 5Tissue Typing Unit, Hadassah, Hebrew University Medical Center, Jerusalem, Israel
  6. 6Department of Pediatric Hematology-Oncology, Hadassah University Hospital, Jerusalem, Israel
  7. 7Department of Biochemistry and Molecular Biology, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
  1. Correspondence to Professor Orly Elpeleg, Department of Genetic and Metabolic Diseases, Hadassah, Hebrew University Medical Center, Jerusalem 91120, Israel; elpeleg{at}


Background Osteopetrosis is a life-threatening, rare disorder typically resulting from osteoclast dysfunction and infrequently from failure to commitment to osteoclast lineage. Patients commonly present in infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, and bone marrow failure. In ∼70% of the patients there is a molecularly defined failure to maintain an acid pH at the osteoclast-bone interface (the ruffled border) which is necessary for the bone resorptive activity.

Methods and results In eight patients with infantile osteopetrosis which could be cured by bone marrow transplantation, the study identified by homozygosity mapping in distantly related consanguineous pedigrees a missense mutation in a highly conserved residue in the SNX10 gene. The mutation segregated with the disease in the families and was carried by one of 211 anonymous individuals of the same ethnicity. In the patients' osteoclasts, the mutant SNX10 protein was abnormally abundant and its distribution altered. The patients' osteoclasts were fewer and smaller than control cells, their resorptive capacity was markedly deranged, and the endosomal pathway was perturbed as evidenced by the distribution of internalised dextran.

Conclusions SNX10 was recently shown to interact with vacuolar type H+-ATPase (V-ATPase) which pumps protons at the osteoclast-bone interface. Mutations in TCIRG1, the gene encoding a subunit of the V-ATPase complex, account for the majority of cases of osteopetrosis. It is speculated that SNX10 is responsible for the vesicular sorting of V-ATPase from Golgi or for its targeting to the ruffled border. A mutation in SNX10 may therefore result in ‘secondary V-ATPase deficiency’ with a failure to acidify the resorption lacuna. Determination of the sequence of the SNX10 gene is warranted in molecularly undefined patients with recessive ‘pure’ osteopetrosis of infancy.

  • Osteopetrosis
  • SNX10
  • endosomal/lysosomal pathway
  • academic medicine
  • haematology (incl blood transfusion)
  • immunology (including allergy)
  • genetics
  • calcium and bone
  • cell biology
  • genetics
  • neuromuscular disease
  • molecular genetics
View Full Text

Statistics from


  • Funding This study was supported by the Hadassah-Hebrew University Joint Foundation grant to SH.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by Hadassah Helsinki committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.